Dow Jones ETF DIA rises as tech slips and Trump defense headlines jar Wall Street before payrolls
8 January 2026
1 min read

Dow Jones ETF DIA rises as tech slips and Trump defense headlines jar Wall Street before payrolls

New York, January 8, 2026, 13:49 EST — Regular session

The SPDR Dow Jones Industrial Average ETF Trust (DIA) rose 0.6% to $492.73 in afternoon trade on Thursday, tracking a gain in the Dow as investors bought steady “old economy” names and trimmed big tech. The Dow was up 304 points, or 0.6%, around midday, while the Nasdaq slipped as heavyweight tech stocks fell. “It’s too soon to call it a broadening of the rally beyond tech stocks,” said Joe Saluzzi, partner and co-founder at Themis Trading. 1

The shift matters because the Dow is still hovering not far from 50,000 after a record close earlier in the week, and traders are trying to read whether leadership is finally spreading out. Stocks are also heading into the next set of labor readings with valuations still rich by recent standards, a setup that can punish crowded trades fast. 2

Wednesday’s pullback showed how jumpy the tape is near record highs. The Dow fell 0.94% to 48,996.08, even as the Nasdaq eked out a gain, after job openings dropped more than expected and private payrolls data came in soft ahead of Friday’s government jobs report. 3

Politics and policy are leaking into sector moves again. Defense shares jumped after President Donald Trump called for a $1.5 trillion U.S. military budget in 2027, up from $901 billion approved for 2026, a proposal that would still need Congress. The rebound came a day after an executive order threatened to block dividends and buybacks at defense contractors until weapons production improves. 4

On the data side, weekly jobless claims rose 8,000 to 208,000, while continuing claims climbed to 1.914 million, pointing to a labor market with limited hiring and limited firing. A separate report showed third-quarter productivity jumped at a 4.9% annualized rate, and “firms are successfully doing more with less labor,” said Matthew Martin, senior U.S. economist at Oxford Economics. 5

Investors are also weighing whether cooling jobs data is enough to pull the Federal Reserve back toward rate cuts. The Chicago Fed estimated the unemployment rate held at 4.6% in December, while economists expect the official jobless rate to dip to 4.5% in Friday’s report; financial markets were pricing about a 10% chance of a cut at the Fed’s Jan. 27-28 meeting, rising to roughly 55% by April. 6

Housing policy is another wild card that can ricochet into Dow-linked industrial and consumer names. Trump said the U.S. would ban large institutional investors from buying single-family homes, a threat that has already stirred debate over who is driving home prices and how much supply is really the problem. 7

But the setup cuts both ways. A stronger-than-expected payrolls print or hotter wage gains could push yields higher and put pressure back on long-duration growth stocks, while a weaker report might revive rate-cut bets even as it raises questions about demand.

Next up is Friday’s U.S. nonfarm payrolls report for December, with traders watching the unemployment rate and wage growth for clues on how quickly the Fed can move.

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Visa stock slips as SEC filing presses independent chair vote ahead of annual meeting
Previous Story

Visa stock slips as SEC filing presses independent chair vote ahead of annual meeting

Barrick gold stock slips mid-session as payrolls loom; HSBC flags $5,000 gold risk
Next Story

Barrick gold stock slips mid-session as payrolls loom; HSBC flags $5,000 gold risk

Go toTop